Key result
Heart failure with mid-range ejection fraction (HFmrEF) represents a heterogeneous clinical entity with characteristics intermediate between HFrEF and HFpEF, requiring further research to define optimal targeted therapies.
Why the study?
To summarize current knowledge regarding the clinical epidemiology, pathophysiology, prognosis, and potentially beneficial therapies for HFmrEF in comparison to HFrEF and HFpEF.
Answers are grounded in this paper and cite their sources.
HFmrEF represents a heterogeneous clinical entity that shares characteristics with both HFrEF and HFpEF, highlighting the need for tailored therapeutic strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2021) conducted a review in Heart failure with mid-range ejection fraction (HFmrEF). Heart failure with mid-range ejection fraction (HFmrEF) represents a heterogeneous clinical entity with characteristics intermediate between HFrEF and HFpEF, requiring further research to define optimal targeted therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: